Von Seggern Christopher 4
4 · Xenon Pharmaceuticals Inc. · Filed Mar 14, 2022
Insider Transaction Report
Form 4
Von Seggern Christopher
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-03-10+100,000→ 100,000 totalExercise: $30.01Exp: 2032-03-09→ Common Shares (100,000 underlying)
Footnotes (1)
- [F1]Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.